[ad_1]
Jakarta, CNBC Indonesia – The Chinese vaccine company Sinovac will delay the publication of its report on the efficacy of the Covid-19 vaccine. This follows the company’s desire to consolidate clinical trial reports from three countries, namely Brazil, Turkey, and Indonesia. The report is expected to be released in January.
The Wall Street Journal report, Brazil, the first country to complete the CoronaVac phase 3 trial, is expected to announce the full efficacy level of the vaccine on Wednesday (12/23/2020). However, Brazil’s Instituto Butantan, a research center supported by the São Paulo state government, said that Sinovac requested 15 more days to analyze the data along with the results of other vaccine trials, which are also being tested in Indonesia and Turkey. Although they felt that this could not be happening,
“There cannot be three efficacy results for the same vaccine,” said Butantan director Dimas Covas. He said the delay had nothing to do with the efficacy of the vaccine, which is expected to be one of the first to be approved for use in Brazil.
Scientists tracking the vaccine hope that CoronaVac will be comparable to other Covid-19 vaccines that have been shown to be 95% effective.
Luiz Carlos Dias, part of the Covid-19 research working group at the University of Campinas in São Paulo state, said this raises new concerns about the efficacy of the vaccine. Despite the fact that the country of Samba has high hopes for this vaccine considering that CoronaVac is the only vaccine that Brazil has so far.
“It’s very frustrating … this is the only vaccine that we currently have on Brazilian soil. I’m afraid it might not be that high.” Call Luiz
The Sinovac vaccine was previously reported to be above the 50% clinical trial threshold, so it was felt that it could protect humans. However, there has been no further release regarding this matter due to the delay requested by Sinovac.
In addition to Brazil, clinical trials of the CoronaVac vaccine were also conducted in Turkey and Indonesia. In Indonesia, until now, the Food and Drug Administration (BPOM) is still testing the vaccine for an emergency distribution permit. But even so, Indonesia has ordered nearly 40 million doses of the vaccine from China.
[Gambas:Video CNBC]
(drums / drums)
